Literature DB >> 15950080

Lipid profile and anticardiolipin antibodies in Behcet's disease.

Ugur Musabak1, Orhan Baylan, Turker Cetin, Zeki Yesilova, Ali Sengul, Kenan Saglam, Ali Inal, Ismail H Kocar.   

Abstract

BACKGROUND: Behcet's disease (BD) is a multisystem disorder characterized by a relapsing inflammatory process of unknown etiology. It is well known that atherothrombosis in systemic inflammatory disorders is closely related to coagulation and lipid metabolism abnormalities. The purpose of this study was to investigate some parameters of lipid metabolism, lipoprotein (a) [Lp(a)] and anticardiolipin antibody (ACA) levels and the relationship of these parameters with the clinical activity of BD.
METHODS: Thirty three patients with BD (15 active, 18 inactive cases) and 20 healthy controls participated in the study. After performing a detailed physical exam, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), very-low-density lipoprotein cholesterol (VLDL-C), apoprotein A and B (apo-A, apo-B), Lp(a), and ACA levels (ACA-IgG and IgM) were measured in all participants.
RESULTS: Patients with active BD had higher ESR, CRP and Lp(a) levels, and lower apo-A and HDL-C levels compared with the patients with inactive BD and healthy controls. ACA-IgG and IgM levels were higher in patients with active BD than healthy controls but not higher than patients with inactive BD. On the other hand, ACA-IgG level was higher in active and inactive cases with vascular involvement than in those of active and inactive cases without vascular involvement. In the analyses of correlation, in active BD patients we found a positive correlation between CRP and Lp(a) levels.
CONCLUSIONS: Our findings suggest that Lp(a) behaves as an acute phase reactant and ACA levels are increased in patients with active BD. Data from patients with active BD may be compatible with the serum profile, which is accepted as a risk for the development of atherothrombosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15950080     DOI: 10.1016/j.arcmed.2005.03.019

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  5 in total

1.  Endothelial expression of human ABCA1 in mice increases plasma HDL cholesterol and reduces diet-induced atherosclerosis.

Authors:  Boris L Vaisman; Stephen J Demosky; John A Stonik; Mona Ghias; Cathy L Knapper; Maureen L Sampson; Cuilian Dai; Stewart J Levine; Alan T Remaley
Journal:  J Lipid Res       Date:  2011-10-27       Impact factor: 5.922

Review 2.  Etiopathogenesis of Behçet's disease with emphasis on the role of immunological aberrations.

Authors:  Violetta D Kapsimali; Meletios A Kanakis; George A Vaiopoulos; Phaedon G Kaklamanis
Journal:  Clin Rheumatol       Date:  2010-05-22       Impact factor: 2.980

3.  Auto-immunity profile evaluation during different clinical manifestations of Behçet disease in Algerian patients: effect of corticosteroid treatment.

Authors:  Fatmazohra Djaballah-Ider; Abdelhamid Djaballah; Zineb Djeraba; Samia Chaib; Chafia Touil-Boukoffa
Journal:  Inflammopharmacology       Date:  2019-02-05       Impact factor: 4.473

4.  Prevalence of antiphospholipid antibodies in Behçet's disease: A systematic review and meta-analysis.

Authors:  Md Asiful Islam; Sayeda Sadia Alam; Shoumik Kundu; A H M Safayet Ullah Prodhan; Shahad Saif Khandker; Tatiana Reshetnyak; Przemysław J Kotyla; Rosline Hassan; Tareq Hossan
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

5.  Investigation of clinical profile of Behçet's syndrome-related versus idiopathic branch retinal vein occlusion.

Authors:  Didar Ucar; Burak Mergen; Busenur Gonen; Yesim Ozguler; Emire Seyahi; Vedat Hamuryudan; Yilmaz Ozyazgan
Journal:  Indian J Ophthalmol       Date:  2020-09       Impact factor: 1.848

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.